Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576155 · ClinicalTrials.gov registry record · Early Phase 1
Sex Differences in the Dilatory Response of Compound 21
A Early Phase 1 study of Sex Differences, sponsored by Anna Stanhewicz, PhD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT05576155 is a Early Phase 1 study of Sex Differences that has completed, run by Anna Stanhewicz, PhD. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05576155, a Early Phase 1 study of Sex Differences, has completed, sponsored by Anna Stanhewicz, PhD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
When blood pressure changes, Angiotensin II is produced and released into the bloodstream. This substance can make blood vessels smaller (i.e., vasoconstriction) by acting through Angiotensin II type I receptors (AT1R) to increase blood pressure. Or it can increase the diameter of vessels (i.e., vasodilation) through Angiotensin II type II receptors (AT2R) to decrease blood pressure. These two receptors normally work in balance to maintain blood pressure. However, excess Angiotensin II released in the bloodstream may reduce the sensitivity of AT2Rs, leading to excessive activation of AT1Rs. This results in increased constriction which plays a major role in diseases such as high blood pressure, hardening of the arteries, and heart failure. In the body, Angiotensin II production is reduced in the presence of estrogen, as seen in pre-menopausal women. Pre-menopausal women have a greater protection against cardiovascular diseases compared to age-matched males, likely due to the protective effects of estrogen. However, the extent that estrogen may impact the sensitivity of Angiotensin II receptors in pre-menopausal is unknown. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents), the blood vessels in a dime-sized area of the skin are studied in healthy young women and men. As a compliment to these measurements, blood is drawn from the subjects and circulating factors that may contribute to cardiovascular health are measured.
Conditions Studied
Interventions
- DRUG Compound 21
- DRUG Compound 21 + losartan
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-02-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05576155
The ClinicalTrials.gov registry entry for NCT05576155 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sex Differences appearing as the primary indexed condition, and to 2 interventions - of which Compound 21 is the first listed.
NCT05576155 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05576155 about?
NCT05576155 is a clinical study titled "Sex Differences in the Dilatory Response of Compound 21". When blood pressure changes, Angiotensin II is produced and released into the bloodstream. This substance can make blood vessels smaller (i.e., vasoconstriction) by acting through Angiotensin II type I receptors (AT1R) to increase blood pressure. Or it can increase the diameter of vessels (i.e., vas...
What is the current status of trial NCT05576155?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2022-10-03. Estimated completion is 2023-02-23.
What conditions does trial NCT05576155 study?
This clinical trial studies the following conditions: Sex Differences.
What interventions are being tested in trial NCT05576155?
The interventions under investigation include: Compound 21 (DRUG), Compound 21 + losartan (DRUG).
Who is sponsoring clinical trial NCT05576155?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05576155 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.